35 related articles for article (PubMed ID: 38684041)
1. Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase-mutant Astrocytic and Oligodendroglial Tumors.
Kamson DO; Puri S; Sang Y; Shi MJ; Blair L; Blakeley JO; Laterra J
Clin Cancer Res; 2023 Dec; 29(23):4863-4869. PubMed ID: 37382607
[TBL] [Abstract][Full Text] [Related]
2. Motor seizures confer overall survival benefit in who grade 2 glioma.
Fairclough S; Chumas P; Goodden J; Maguire M; Mathew RK
Epilepsia; 2024 Jun; 65(6):1679-1686. PubMed ID: 38506645
[TBL] [Abstract][Full Text] [Related]
3. Genetically Distinct Oligosarcoma Arising from Oligodendroglioma: Systematic Review & Illustrative Case Example.
Evans AR; Prather KY; Battiste J; Fung KM; Dunn IF; Graffeo CS
World Neurosurg; 2024 May; 185():e1093-e1100. PubMed ID: 38490447
[TBL] [Abstract][Full Text] [Related]
4. Epilepsy in gliomas: recent insights into risk factors and molecular pathways.
Rudà R; Bruno F; Pellerino A
Curr Opin Neurol; 2023 Dec; 36(6):557-563. PubMed ID: 37865836
[TBL] [Abstract][Full Text] [Related]
5. Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network.
Esparragosa Vazquez I; Sanson M; Chinot OL; Fontanilles M; Rivoirard R; Thomas-Maisonneuve L; Cartalat S; Tabouret E; Appay R; Bonneville-Levard A; Darlix A; Meyronet D; Barritault M; Gueyffier F; Remontet L; Maucort-Boulch D; Honnorat J; Dehais C; Ducray F;
Neurooncol Adv; 2024; 6(1):vdae078. PubMed ID: 38855053
[TBL] [Abstract][Full Text] [Related]
6. Association of CDKN2A alterations with increased postoperative seizure risk after resection of brain metastases.
Cummins DD; Garcia JH; Nguyen MP; Saggi S; Chung JE; Goldschmidt E; Berger MS; Theodosopoulos PV; Chang EF; Daras M; Hervey-Jumper SL; Aghi MK; Morshed RA
Neurosurg Focus; 2023 Aug; 55(2):E14. PubMed ID: 37527678
[TBL] [Abstract][Full Text] [Related]
7. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy.
Yang Y; Mao Q; Wang X; Liu Y; Mao Y; Zhou Q; Luo J
J Clin Neurosci; 2016 Sep; 31():56-62. PubMed ID: 27406953
[TBL] [Abstract][Full Text] [Related]
8. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
Ammendola S; Broggi G; Barresi V
Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
[TBL] [Abstract][Full Text] [Related]
9. Seizures in patients with IDH-mutated lower grade gliomas.
Carstam L; Rydén I; Jakola AS
J Neurooncol; 2022 Nov; 160(2):403-411. PubMed ID: 36258151
[TBL] [Abstract][Full Text] [Related]
10. Molecular Classification of Gliomas is Associated with Seizure Control: A Retrospective Analysis.
Easwaran TP; Lancki N; Henriquez M; Vortmeyer AO; Barbaro NM; Scholtens DM; Ahmed AU; Dey M
Neuromolecular Med; 2021 Jun; 23(2):315-326. PubMed ID: 33206320
[TBL] [Abstract][Full Text] [Related]
11. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
[TBL] [Abstract][Full Text] [Related]
12. Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
Franceschi E; Tosoni A; De Biase D; Lamberti G; Danieli D; Pizzolitto S; Zunarelli E; Visani M; Di Oto E; Mura A; Minichillo S; Scafati C; Asioli S; Paccapelo A; Bartolini S; Brandes AA
Oncologist; 2019 May; 24(5):664-670. PubMed ID: 30777895
[TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
[TBL] [Abstract][Full Text] [Related]
14. Association of Clinical, Tumor, and Treatment Characteristics With Seizure Control in Patients With
Bruno F; Pellerino A; Conti Nibali M; Pronello E; Cofano F; Rossi M; Levis M; Bertero L; Soffietti R; Cassoni P; Garbossa D; Bello L; Rudà R
Neurology; 2024 May; 102(10):e209352. PubMed ID: 38684041
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
